Sunday, August 12, 2012

AB Science announces data from development program of masitinib in GIST

In continuation of my update on Masitinib
AB Science announces data from development program of masitinib in GIST: AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces today that data from the development program of masitinib in gastrointestinal stromal tumors (GIST) have been presented as part of three presentations delivered at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting, 1-5 June in Chicago, Illinois.

No comments: